CR20210514A - Use of reboxetine to treat narcolepsy - Google Patents

Use of reboxetine to treat narcolepsy

Info

Publication number
CR20210514A
CR20210514A CR20210514A CR20210514A CR20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A CR 20210514 A CR20210514 A CR 20210514A
Authority
CR
Costa Rica
Prior art keywords
reboxetine
narcolepsy
cataplexy
treat narcolepsy
treat
Prior art date
Application number
CR20210514A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CR20210514A publication Critical patent/CR20210514A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
CR20210514A 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy CR20210514A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (1)

Publication Number Publication Date
CR20210514A true CR20210514A (en) 2021-11-12

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210514A CR20210514A (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Country Status (16)

Country Link
EP (1) EP3866768A4 (en)
JP (1) JP2022504975A (en)
KR (1) KR20210071046A (en)
CN (1) CN112888430A (en)
AU (2) AU2019361915A1 (en)
BR (1) BR112021007019A2 (en)
CA (1) CA3115983A1 (en)
CL (1) CL2021000924A1 (en)
CO (1) CO2021004681A2 (en)
CR (1) CR20210514A (en)
EC (1) ECSP21031200A (en)
IL (1) IL282311A (en)
MX (1) MX2021004207A (en)
PE (1) PE20211199A1 (en)
SG (1) SG11202103588WA (en)
WO (1) WO2020081461A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20230055668A (en) * 2021-10-19 2023-04-26 단국대학교 천안캠퍼스 산학협력단 Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
KR20070029740A (en) * 2004-06-09 2007-03-14 화이자 인코포레이티드 Use of reboxetine for the treatment of pain
DK2968208T3 (en) * 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd TREATMENT OF CATAPLEXIA

Also Published As

Publication number Publication date
EP3866768A4 (en) 2022-01-05
EP3866768A1 (en) 2021-08-25
CA3115983A1 (en) 2020-04-23
MX2021004207A (en) 2021-08-11
CN112888430A (en) 2021-06-01
AU2023200917A1 (en) 2023-03-23
CO2021004681A2 (en) 2021-06-21
CL2021000924A1 (en) 2021-09-03
IL282311A (en) 2021-05-31
ECSP21031200A (en) 2021-05-31
PE20211199A1 (en) 2021-07-01
AU2019361915A1 (en) 2021-05-13
WO2020081461A1 (en) 2020-04-23
SG11202103588WA (en) 2021-05-28
JP2022504975A (en) 2022-01-13
KR20210071046A (en) 2021-06-15
BR112021007019A2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
PH12020500555A1 (en) Esketamine for the treatment of depression
MX2021004207A (en) Use of reboxetine to treat narcolepsy.
MX2019009227A (en) Methods for treating cancer using hsp90 inhibitors.
MX2022010357A (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis.
CY1123501T1 (en) USE OF RESLIZUMAB IN THE TREATMENT OF MODERATE TO SEVERE EOSINOPHILIC ASTHMA
MX2020001727A (en) Combination therapy.
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
MX2023004156A (en) Combination therapy for treating cancer.
MX2020011817A (en) Methods for treating lymphoma.
MX2021002322A (en) Novel methods.
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2020001768A (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
CR20210507A (en) Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
MX2020001254A (en) Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor.
MX2022005250A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies.
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
EA202091653A1 (en) MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
MX2022006630A (en) Use of reboxetine to treat nervous system disorders.
MX2022004785A (en) Methods and compositions for treatment of rett syndrome.
EA202190294A1 (en) COMBINATION THERAPY FOR CANCER TREATMENT
AR122344A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS